サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1781394

リシノプリルの世界市場

Lisinopril

出版日
ページ情報
英文 476 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.69円
リシノプリルの世界市場
出版日: 2025年08月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 476 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

リシノプリルの世界市場は2030年までに18億米ドルに達する

2024年に15億米ドルと推定されるリシノプリルの世界市場は、2024年から2030年にかけてCAGR 3.2%で成長し、2030年には18億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるタブレットは、CAGR 2.4%を記録し、分析期間終了までに11億米ドルに達すると予測されます。リキッドセグメントの成長率は、分析期間中CAGR 4.3％と推定されます。

米国市場は4億1,550万米ドルと推定、中国はCAGR 5.8％で成長すると予測

米国のリシノプリル市場は、2024年には4億1,550万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.8%として、2030年までに3億5,930万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と2.4%と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界のリシノプリル市場- 主要動向と促進要因まとめ

リシノプリルが高血圧および心血管疾患治療のキープレイヤーである理由とは？

アンジオテンシン変換酵素（ACE）阻害薬として広く処方されているリシノプリルは、高血圧、心不全、心筋梗塞後の治療において重要な役割を果たしています。血管を弛緩させることで血圧を下げ、心臓の負担を軽減し、心血管系の健康全般を改善する作用が高く評価されています。リシノプリルの長年にわたる有効性、手頃な価格、確立された安全性プロファイルにより、ヘルスケアプロバイダーや患者から好まれています。他の降圧剤とは異なり、リシノプリルは1日1回の投与で、患者のコンプライアンスと治療計画の遵守を高めることで知られています。その他の特典としては、腎保護作用があるため、世界の糖尿病患者の増加傾向にある糖尿病性腎症患者に特に有効です。心血管疾患の重大な危険因子である高血圧の有病率の増加は、先進国市場でも新興国市場でもリシノプリルの需要を煽っています。都市化、座りがちな生活習慣、食生活の変化により、生活習慣病が増加の一途をたどる中、リシノプリルは降圧療法に不可欠な成分であり続け、市場での地位をさらに強固なものにしています。

リシノプリル市場における主な技術および製剤上の進歩とは？

製剤と製造プロセスにおける革新は、リシノプリルの成長と入手のしやすさに大きく貢献しています。製薬会社は、特に低・中所得国において、市場へのリーチと購入しやすい価格を拡大するため、高品質のジェネリック医薬品の製造に注力しています。リシノプリルとヒドロクロロチアジドのような他の降圧剤との合剤治療が可能になったことで、治療効果と患者の利便性がさらに向上しました。さらに、口腔内崩壊錠や徐放性製剤などのドラッグデリバリー機構の進歩は、バイオアベイラビリティと患者のアドヒアランスの向上を目指しています。また、遠隔医療や電子薬局の普及により、リシノプリルへのアクセスが効率化され、患者が便利に処方箋を入手できるようになっています。市場のもう一つの注目すべき動向は、規制要件や環境への配慮から、持続可能でコスト効率の高い製造方法に注目が集まっていることです。企業は、薬剤の安定性を最適化し、製剤特性を向上させるために、新しい賦形剤技術を活用しています。研究開発への継続的な投資により、リシノプリル市場は、進化する患者のニーズや治療ガイドラインに沿ったドラッグデリバリーや併用療法のさらなる技術革新が見られると予測されます。

市場需要はリシノプリル業界の成長にどのような影響を与えているか？

高血圧や心血管疾患の負担増は、リシノプリルの需要に大きな影響を与えています。世界の保健機関によると、世界中で約13億人が高血圧症に苦しんでおり、降圧剤の膨大な市場の可能性を浮き彫りにしています。高血圧関連の合併症を起こしやすい老年人口の増加が、リシノプリルの需要をさらに押し上げています。さらに、心血管疾患の経済的負担を軽減することを目的とした政府のヘルスケアイニシアチブと償還プログラムにより、病院と小売薬局の両方でリシノプリルへのアクセスが拡大しています。また、健康意識の高まり、予防医療、定期的な健康診断により、高血圧の早期発見と管理が進み、リシノプリルの売上を促進しています。さらに、製薬会社は市場での存在感を高めるため、流通網を拡大し、戦略的パートナーシップを結んでいます。また、一部の地域ではセルフメディケーションの動向や降圧薬の市販も市場拡大に寄与しています。個別化医療やプレシジョン・ヘルスケアが普及するにつれ、降圧治療を個々の患者のプロファイルに合わせて調整することが重視されるようになっており、これが処方動向やリシノプリルに基づく治療の採用に影響を与える可能性があります。

リシノプリル市場の主な成長促進要因は？

リシノプリル市場の成長は、高血圧の有病率の上昇、医療費の増加、ジェネリック医薬品の利用拡大など、いくつかの重要な要因によってもたらされます。主な促進要因の1つは、特に医療へのアクセスが課題となっている新興市場において、費用対効果が高く、忍容性の高い降圧薬に対する強い需要があることです。また、糖尿病や腎障害などの慢性疾患の急増も、腎機能に対する保護作用を考慮したリシノプリルの使用量増加に寄与しています。もう一つの重要な成長要因は、高血圧治療の第一選択薬としてリシノプリルのようなACE阻害薬を優先する、エビデンスに基づいた治療ガイドラインが重視されるようになってきたことです。さらに、製薬会社は、薬価の引き下げや政府・非政府組織との戦略的提携を通じて、医薬品の値ごろ感や入手しやすさの向上に継続的に取り組んでいます。オンライン薬局やテレヘルスプラットフォームの普及など、ヘルスケア業界におけるデジタル変革の進行により、リシノプリルはより幅広い患者層が容易に利用できるようになりました。心血管疾患や代謝性疾患の調査が進むにつれて、リシノプリルの長期的な効果に関する臨床的な洞察がさらに深まり、治療プロトコルにおけるリシノプリルの地位が強化される可能性があります。有利な市場力学、規制当局のサポート、継続的な医学的進歩の組み合わせにより、リシノプリル市場は今後数年間も安定した成長軌道を維持すると予想されます。

セグメント

投与（錠剤、液剤）、投与強度（10mg、20mg、25mg）、流通チャネル（病院薬局、小売薬局、オンライン薬局）、最終用途（高血圧、心不全、心臓発作、糖尿病性腎臓病、その他の用途）

調査対象企業の例

  • AbbVie Inc.
  • Actavis Elizabeth LLC
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc（GSK）
  • Hetero Drugs
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila Healthcare Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31852

Global Lisinopril Market to Reach US$1.8 Billion by 2030

The global market for Lisinopril estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Tablet, one of the segments analyzed in the report, is expected to record a 2.4% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Liquid segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$415.5 Million While China is Forecast to Grow at 5.8% CAGR

The Lisinopril market in the U.S. is estimated at US$415.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$359.3 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Lisinopril Market - Key Trends & Drivers Summarized

Why is Lisinopril a Key Player in the Treatment of Hypertension and Cardiovascular Diseases?

Lisinopril, a widely prescribed angiotensin-converting enzyme (ACE) inhibitor, plays a crucial role in the treatment of hypertension, heart failure, and post-myocardial infarction management. It is highly valued for its ability to lower blood pressure by relaxing blood vessels, reducing the workload on the heart, and improving overall cardiovascular health. Lisinopril’s long-standing efficacy, affordability, and established safety profile have made it a preferred choice among healthcare providers and patients alike. Unlike other antihypertensive drugs, lisinopril is known for its once-daily dosing, which enhances patient compliance and adherence to treatment regimens. Additionally, the drug's renoprotective benefits make it particularly beneficial for patients with diabetic nephropathy, a growing concern in the global diabetic population. The increasing prevalence of hypertension, which is a significant risk factor for cardiovascular diseases, has fueled the demand for lisinopril in both developed and developing markets. As lifestyle-related diseases continue to rise due to urbanization, sedentary habits, and dietary changes, lisinopril remains an essential component in antihypertensive therapy, further reinforcing its strong market position.

What Are the Key Technological and Formulation Advancements in the Lisinopril Market?

Innovations in drug formulation and manufacturing processes have significantly contributed to the growth and accessibility of lisinopril. Pharmaceutical companies are focusing on producing high-quality generic versions to expand market reach and affordability, especially in low- and middle-income countries. The availability of fixed-dose combination therapies that incorporate lisinopril with other antihypertensive agents, such as hydrochlorothiazide, has further enhanced treatment efficacy and patient convenience. Additionally, advancements in drug delivery mechanisms, including orally disintegrating tablets and extended-release formulations, aim to improve bioavailability and patient adherence. The increasing adoption of telemedicine and e-pharmacies has also streamlined access to lisinopril, allowing patients to conveniently obtain their prescriptions. Another notable trend in the market is the focus on sustainable and cost-efficient manufacturing practices, driven by regulatory requirements and environmental considerations. Companies are leveraging novel excipient technologies to optimize drug stability and enhance formulation properties. With continued investment in research and development, the lisinopril market is poised to witness further innovation in drug delivery and combination therapies that align with evolving patient needs and treatment guidelines.

How Is Market Demand Influencing the Growth of the Lisinopril Industry?

The growing burden of hypertension and cardiovascular diseases has significantly influenced the demand for lisinopril. According to global health organizations, nearly 1.3 billion people worldwide suffer from hypertension, highlighting the vast market potential for antihypertensive drugs. The increasing geriatric population, which is more susceptible to hypertension-related complications, has further driven the demand for lisinopril. Additionally, government healthcare initiatives and reimbursement programs aimed at reducing the economic burden of cardiovascular diseases have facilitated greater access to lisinopril in both hospital and retail pharmacy settings. The rise in health awareness, preventive care, and routine health check-ups has also led to early detection and management of hypertension, propelling lisinopril sales. Furthermore, pharmaceutical companies are expanding their distribution networks and engaging in strategic partnerships to strengthen their market presence. The trend of self-medication and over-the-counter availability of antihypertensive drugs in certain regions has also contributed to market expansion. As personalized medicine and precision healthcare gain traction, there is a growing emphasis on tailoring antihypertensive treatments to individual patient profiles, which may influence prescribing trends and the adoption of lisinopril-based therapies.

What Are the Primary Growth Drivers Fueling the Lisinopril Market?

The growth in the lisinopril market is driven by several key factors, including the rising prevalence of hypertension, increasing healthcare expenditure, and expanding generic drug availability. One of the primary drivers is the strong demand for cost-effective and well-tolerated antihypertensive medications, particularly in emerging markets where healthcare accessibility remains a challenge. The surge in chronic diseases, such as diabetes and kidney disorders, has also contributed to the increased usage of lisinopril, given its protective effects on kidney function. Another critical growth driver is the growing emphasis on evidence-based treatment guidelines that prioritize ACE inhibitors like lisinopril for first-line hypertension management. Additionally, pharmaceutical companies are continuously working to enhance drug affordability and accessibility through price reductions and strategic collaborations with government and non-government organizations. The ongoing digital transformation in the healthcare industry, including the proliferation of online pharmacies and telehealth platforms, has made lisinopril more readily available to a broader patient base. As research into cardiovascular and metabolic diseases advances, further clinical insights into lisinopril’s long-term benefits may strengthen its position in treatment protocols. With a combination of favorable market dynamics, regulatory support, and continuous medical advancements, the lisinopril market is expected to sustain its steady growth trajectory in the coming years.

SCOPE OF STUDY:

The report analyzes the Lisinopril market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Dosage (Tablet, Liquid); Dosage Strength (10 mg, 20 mg, 25 mg); Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy); End-Use (Hypertension, Heart failure, Heart attack, Diabetic kidney disease, Other applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Actavis Elizabeth LLC
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • Hetero Drugs
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila Healthcare Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Lisinopril - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Hypertension and Cardiovascular Diseases Drives Demand for Lisinopril Prescriptions
    • Widening Use of ACE Inhibitors in Heart Failure Management Throws the Spotlight on Lisinopril's Clinical Relevance
    • Generic Drug Market Expansion Strengthens Business Case for Lisinopril-Based Cost-Effective Treatment Protocols
    • Regulatory Endorsements for First-Line Therapy in Hypertension Accelerate Physician Adoption of Lisinopril
    • Increasing Integration of Lisinopril in Combination Therapies Spurs Market for Fixed-Dose Antihypertensive Regimens
    • OEM Focus on Once-Daily Formulations Enhances Patient Compliance and Improves Treatment Outcomes
    • Surging Prevalence of Diabetic Nephropathy Generates Demand for Renoprotective Hypertension Therapies
    • Expanded Use of Lisinopril in Post-Myocardial Infarction Recovery Supports Cardioprotective Drug Protocols
    • Rising Availability of Government-Subsidized Generics Strengthens Access in Emerging Economies
    • Widespread Clinical Familiarity With ACE Inhibitors Propels Continued Preference Over Novel Agents
    • Cost-Containment Pressures in Public Healthcare Systems Drive Demand for Affordable Lisinopril Formulations
    • Increased Inclusion in Multinational Hypertension Treatment Guidelines Supports Long-Term Demand Sustainability
    • Focus on Population Health Management Strategies Promotes Standardized Lisinopril-Based Care Pathways
    • Growth in Online Pharmacies and Telehealth Expands Consumer Access to Lisinopril Prescriptions
    • OEM Investment in Modified-Release and Low-Dose Formulations Drives Innovation Within Generic Framework
    • Rising Emphasis on Medication Adherence in Chronic Disease Management Strengthens Demand for Reliable ACE Inhibitors
    • Expansion of Insurance Coverage and Formularies in Low-Income Markets Fuels Generic Lisinopril Adoption
    • Clinical Comparisons With ARBs Reinforce Lisinopril's Utility in Cost-Sensitive Settings
    • Increased Use of Lisinopril in Elderly Populations With Multiple Comorbidities Sustains Therapeutic Versatility
    • Regulatory Stability and Supply Chain Maturity in Generic APIs Ensures Consistent Global Availability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Lisinopril Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Lisinopril by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Lisinopril by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Lisinopril by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Tablet by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Tablet by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Liquid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Heart failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Heart failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Heart failure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Heart attack by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Heart attack by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Heart attack by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diabetic kidney disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diabetic kidney disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Diabetic kidney disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hypertension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for 10 mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for 10 mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for 10 mg by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for 20 mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for 20 mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for 20 mg by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for 25 mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for 25 mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for 25 mg by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospital pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospital pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Hospital pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Retail pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Retail pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Retail pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Online pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Online pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Online pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • JAPAN
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • CHINA
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • EUROPE
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Lisinopril by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Lisinopril by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Lisinopril by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • FRANCE
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • GERMANY
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Lisinopril by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Lisinopril by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • INDIA
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Lisinopril by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Lisinopril by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Lisinopril by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Lisinopril by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Lisinopril by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Lisinopril by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030
  • AFRICA
    • Lisinopril Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Lisinopril by Dosage - Tablet and Liquid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Lisinopril by Dosage - Tablet and Liquid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Lisinopril by Dosage - Percentage Breakdown of Value Sales for Tablet and Liquid for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Lisinopril by End-Use - Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Lisinopril by End-Use - Percentage Breakdown of Value Sales for Heart failure, Heart attack, Diabetic kidney disease, Other applications and Hypertension for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Lisinopril by Dosage Strength - 10 mg, 20 mg and 25 mg Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Lisinopril by Dosage Strength - Percentage Breakdown of Value Sales for 10 mg, 20 mg and 25 mg for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Lisinopril by Distribution Channel - Hospital pharmacy, Retail pharmacy and Online pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Lisinopril by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacy, Retail pharmacy and Online pharmacy for the Years 2015, 2025 & 2030

IV. COMPETITION